Equities

Perspective Therapeutics Inc

Perspective Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.25
  • Today's Change-0.530 / -4.50%
  • Shares traded607.29k
  • 1 Year change+310.73%
  • Beta1.3122
Data delayed at least 15 minutes, as of Nov 09 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments9.244464
Total Receivables, Net1.187.472.05
Total Inventory--1.410.98
Prepaid expenses1.080.550.42
Other current assets, total5.350.030.03
Total current assets175367
Property, plant & equipment, net6.322.062.73
Goodwill, net24----
Intangibles, net500.090.13
Long term investments0.130.15--
Note receivable - long term------
Other long term assets--2.400.08
Total assets985870
LIABILITIES
Accounts payable------
Accrued expenses4.441.141.07
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.05----
Other current liabilities, total5.07----
Total current liabilities162.681.80
Total long term debt1.6800
Total debt1.7300
Deferred income tax4.59----
Minority interest------
Other liabilities, total0.780.771.21
Total liabilities233.453.01
SHAREHOLDERS EQUITY
Common stock0.280.140.14
Additional paid-in capital227160159
Retained earnings (accumulated deficit)(152)(106)(91)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity755567
Total liabilities & shareholders' equity985870
Total common shares outstanding281414
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.